FDA Approves Rexulti For Agitation Associated With Dementia Due To Alzheimer's

The U.S. Food and Drug Administration announced the supplemental approval of Rexulti (brexpiprazole) oral tablets to treat agitation associated with dementia due to Alzheimer's disease.
The U.S. Food and Drug Administration announced the supplemental approval of Rexulti (brexpiprazole) oral tablets to treat agitation associated with dementia due to Alzheimer's disease.

Managing agitation associated with dementia due to Alzheimer's disease - STAT

FDA advisers back Lundbeck and Otsuka's Rexulti in Alzheimer's disease agitation

Rexulti治療失智症躁動怎麼用？第一個美國FDA認可治療阿茲海默失智症躁動(agitation)症狀的藥物- 大腦森林閱讀之旅

Story

Lundbeck, Otsuka secure FDA approval of Rexulti for Alzheimer's-related agitation

BXCL501 seen to ease Alzheimer's agitation in Phase 3 trial, Developer BioXcel to meet with FDA to discuss path to approval

A first: FDA approves drug to treat agitation in Alzheimer's

Brexpiprazole (Rexulti) Approved for Alzheimer's Agitation

FDA's Shocking Approval: Rexulti Fast-Tracked Despite Deadly Risks

FDA approves Rexulti for Alzheimer related agitation - News weather sports for Youngstown-Warren Ohio

US FDA approves Rexulti as first drug for agitation in Alzheimer's dementia

FDA approves supplemental new drug application for Rexulti to treat Alzheimer's agitation

1st drug to treat dementia symptoms approved by FDA, agency says